Biological treatments in beh&#231;et&apos;s disease : beyond anti-TNF therapy by F. Caso et al.
Review Article
Biological Treatments in Behçet’s Disease:
Beyond Anti-TNF Therapy
Francesco Caso,1,2 Luisa Costa,3 Donato Rigante,4 Orso Maria Lucherini,1 Paolo Caso,5
Vittoria Bascherini,1 Bruno Frediani,1 Rolando Cimaz,6 Edoardo Marrani,6
Laura Nieves-Martín,1,7 Mariangela Atteno,3 Carmela G. L. Raffaele,4 Giusyda Tarantino,4
Mauro Galeazzi,1 Leonardo Punzi,2 and Luca Cantarini1
1 Interdepartmental Research Center of Systemic Autoimmune and Autoinflammatory Diseases, Rheumatology Unit,
Policlinico Le Scotte, University of Siena, Viale Bracci 1, 53100 Siena, Italy
2 Rheumatology Unit, Department of Medicine DIMED, University of Padova, Via Giustiniani 2, 35128 Padova, Italy
3 Rheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II, Via S. Pansini 5, 80131 Naples, Italy
4 Institute of Pediatrics, Cattolica Sacro Cuore University, Largo Agostino Gemelli 8, 00168 Rome, Italy
5 La Sapienza University, Viale del Policlinico 155, 00161 Rome, Italy
6Department of Pediatrics, Rheumatology Unit, Anna Meyer Children’s Hospital and University of Florence, Viale Pieraccini 24,
50139 Florence, Italy
7 Rheumatology Service, Hospital Regional Universitario Carlos Haya, University of Ma`laga, Avenida Carlos Haya s/n,
29010 Ma`laga, Spain
Correspondence should be addressed to Luca Cantarini; cantariniluca@hotmail.com
Received 16 January 2014; Revised 17 April 2014; Accepted 1 May 2014; Published 30 June 2014
Academic Editor: Chiara De Luca
Copyright © 2014 Francesco Caso et al.This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Behc¸et’s disease (BD) is universally recognized as a multisystemic inflammatory disease of unknown etiology with chronic course
and unpredictable exacerbations: its clinical spectrum varies from pure vasculitic manifestations with thrombotic complications to
protean inflammatory involvement of multiple organs and tissues. Treatment has been revolutionized by the progressed knowledge
in the pathogenetic mechanisms of BD, involving dysfunction and oversecretion of multiple proinflammatory molecules, chiefly
tumor necrosis factor- (TNF-) 𝛼, interleukin- (IL-) 1𝛽, and IL-6. However, although biological treatment with anti-TNF-𝛼 agents
has been largely demonstrated to be effective in BD, not all patients are definite responders, and this beneficial response might drop
off over time. Therefore, additional therapies for a subset of refractory patients with BD are inevitably needed. Different agents
targeting various cytokines and their receptors or cell surface molecules have been studied: the IL-1 receptor has been targeted by
anakinra, the IL-1 by canakinumab and gevokizumab, the IL-6 receptor by tocilizumab, the IL12/23 receptor by ustekinumab, and
the B-lymphocyte antigen CD-20 by rituximab.The aim of this review is to summarize all current experiences and the most recent
evidence regarding these novel approaches with biological drugs other than TNF-𝛼 blockers in BD, providing a valuable addition
to the actually available therapeutic armamentarium.
1. Introduction
Behc¸et’s disease (BD) is a chronic and relapsing multisys-
temic inflammatory disorder which can be localized on
the borderline between autoimmune and autoinflammatory
diseases [1]. Its incidence is increased around the Mediter-
ranean basin, extending through Middle East and Orient
countries, and from a clinical point of view the disorder
is mainly characterized by recurrent episodes of mucocu-
taneous, ocular, joint, vascular, and central nervous system
involvement. Recurrent oral and/or genital aphthosis, ocular
involvement in terms of uveitis and, retinal vasculitis in
combination with variable skin lesions are the cardinal signs
of BD [2]. Considerable heterogeneity has been observed
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among different cohorts of patients with BD, with life-
threatening arterial and venous vessel inflammation and
thrombotic complications. Furthermore, although somewhat
less frequently, BD patients may show joint, gastrointestinal,
peripheral, and central nervous system and renal, cardiac,
and pulmonary involvement [3]. Its etiology remains still
unknown, but the most accredited hypothesis suggests a
complex interaction between genetic background and envi-
ronmental factors, such as microbial agents or their antigens
(related to herpes simplex virus, streptococci, staphylococci,
or Escherichia species) [4]. Human leukocyte antigen (HLA)-
B 51, one of the numerous split antigens of HLA-B 5, is the
strongest genetic marker of BD in different ethnic groups, as
reported both in genome wide association [5, 6] and in meta-
analysis studies [7–9]. AlthoughHLA-B 51’s mode of action is
unclear, antigen presentation ability, molecular mimicry with
microbial antigens, or participation in linkage disequilibrium
with other genes has been suggested as potential contributive
mechanisms in the pathogenesis of BD [7–9]. However,
major pathogenetic mechanisms underlying BD are linked
to innate immune cell activation and dysregulation, and
hyperactivity of neutrophils, T-helper- (Th-) 1, and Th-17
natural killer (NK) cells, the main result of which is the
critical overproduction of proinflammatory cytokines, such
as tumor necrosis factor- (TNF-) 𝛼, interleukin- (IL-) 1𝛽,
IL-6, and IL-17 [10]. Our improved understanding of the
molecular mechanisms involved in BD has recently opened
up new interesting sceneries in terms of therapy, whichmight
be initiated in the most severely affected patients to avoid
complications, such as vascular thrombosis and neurological
and/or ocular manifestations [3]. Prior to the introduction
of biological agents, options for the treatment of severe BD
were limited. In particular, TNF inhibition was successful
in controlling inflammation in many patients [11]. However,
not all patients responded to different anti-TNF-𝛼 agents,
and loss of efficacy did also appear over time in patients
initially responding to anti-TNF biological drugs. Recently
many reports have begun to describe BD patients in whom
molecular targets other than TNF were sought [12]. The aim
of this review is to summarize all current experience and
evidence about a new therapeutic biological approach in BD
with drugs other than TNF-𝛼 blockers.
2. Cornerstones of Treatment in
Behçet’s Disease
BD clinical course is highly irregular and erratic, ranging
from simple localized mucocutaneous symptoms, that may
or may not be associated with uveitis, to severe forms
associated with eye and neurological involvement linked to
less favourable outcomes. Thus, therapy is mainly based on
the type and severity of clinical manifestations and disease
duration, as well as number of flares [13]. The mainstay of
therapy of isolated aphthosis and acne-like lesions is centred
on topical measures [14]. Colchicine at a daily dosage of 1-
2mg/day can be introduced as an additional option in the
management of mucocutaneous signs, as its efficacy has been
demonstrated in genital aphthosis and erythema nodosum,
as well as in joint involvement displayed by female patients
[15, 16]. However, data on oral aphthosis and pseudofolli-
culitis are controversial [15–17], and azathioprine may be
considered in cases with severe resistant mucocutaneous
and articular involvement [13]. Indeed, azathioprine, usually
administered at a daily dosage of 2.5mg/kg, has been shown
to positively impact the long-term prognosis and frequency
ofmucocutaneous and articularmanifestations of BD [18, 19].
Azathioprine importance lies in its beneficial effects on the
posterior uveitis [18]. In particular, in a two-year randomized
controlled trial in Turkish males with BD, both without
and with eye involvement, azathioprine induced a decrease
in uveitis flares and protected against the recurrence of
uveitis [19]. Thus, its use along with systemic corticosteroids
is recommended in BD patients showing eye involvement
affecting the posterior segment [13]. In addition to azathio-
prine, cyclosporine A, at a daily dosage of 5mg/kg, has
also shown its efficacy on the ocular posterior involvement,
bringing about improvement in visual acuity during the first
6 months of therapy [20]. Its efficacy at a dosage of 10mg/kg
daily has been demonstrated at a short-term followup, with
reduction in both frequency and severity of ocular flares
[21]. However, these dosages cannot be considered in long-
term treatment due to the risk of secondary nephropathy,
hypertension, and neurotoxicity [13]. In addition to azathio-
prine and cyclosporine A, other immunosuppressive drugs
currently used in themanagement of BD include thalidomide
[22], methotrexate [23], and cyclophosphamide [24]. The
absence of consolidated data on the efficacy of methotrexate
and thalidomide in BDkeeps them frombeing recommended
as definite therapeutic strategies [13], although thalidomide
has been shown to be potentially useful in themanagement of
severe gastrointestinal involvement prior to implementation
of other strategies and surgery [13]. Thalidomide, at the
daily dosage ranging from 100 to 300mg, has also been
shown to reduce the frequency of orogenital ulcerations
and pseudofolliculitis, but, due to the teratogenic risk and
frequent peripheral polyneuropathy, its use is limited [22].
The efficacy of methotrexate, usually employed at a dosage
of 7.5–15mg once a week, has been reported just in one
observational study related to posterior uveitis [25]. Efficacy
of cyclophosphamide has been proved in patients with
ocular, vascular, and neurological involvement [24, 26–30].
With regard to ocular involvement, in a recent study, eye
outcomes were evaluated after long-term administration of
cyclophosphamide (1 g pulse of cyclophosphamide monthly
for 6 months and then every 2-3 months as necessary), aza-
thioprine (at a daily dosage of 2-3mg/kg), and prednisolone
(initiated at 0.5mg/kg daily and tapered in case of remis-
sion) in 295 patients: total adjusted disease activity index
significantly improved, but improvement of visual acuity was
unremarkable, due to the onset of secondary cataracts [24].
Early use of cyclophosphamide (at a daily dosage of 1mg/kg
given per os or at a dosage ranging from 750 to 1 g/m2 every 4
weeks given intravenously) has been considered useful for the
vascular complications of BD, including thromboses, occlu-
sions, and large-vessel aneurysms, among the most feared
complications due to high potential morbidity and mortality
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Figure 1: Mechanisms of actions of anakinra, canakinumab, gevokizumab, tocilizumab, ustekinumab, and rituximab, based on the different
mechanisms of antagonizing cytokine receptors, cytokines, and cellular antigens.
risk [26–29]. Patients with severe neurological clinical signs
(meningoencephalitis, dural sinus thrombosis, and severe
peripheral nervous system involvement) also require high-
dose oral or intravenous corticosteroids in association with
cyclophosphamide, at a dosage based on the severity and
location of inflammation [30]. For severe and relapsing BD a
broad spectrum of therapies consisting of interferon [31] and
intravenous immunoglobulins [32] are available, but efficacy
data are limited and conflicting [31–33]. To date, therapy
has been revolutionized by advances in the knowledge
of BD pathogenetic mechanisms, namely, dysfunction and
oversecretion of a network of proinflammatory molecules,
principally TNF-𝛼 [10, 34]. Data on anti-TNF-𝛼 agents are
derived from BD case reports and series of patients who were
resistant to immunosuppressants and corticosteroids, most
of whom suffered from ocular, gastrointestinal, neurological,
and vascular manifestations [35–38]. Among anti-TNF-𝛼
agents, etanercept, a fusion protein of the TNF receptor and
IgG
1
Fc domain, has been shown to reduce the frequency of
oral aphthosis and skin lesions combined with a moderate
improvement of joint manifestations [35].
Infliximab, a chimeric mouse-human anti-TNF-𝛼mono-
clonal antibody, at a dosage of 5mg/kg in combination with
an immunosuppressive agent, has induced a rapid remis-
sion of eye refractory inflammatory signs [39]. Additionally,
infliximab, combined with corticosteroids and/or immuno-
suppressive agents such as cyclosporine A or azathioprine,
may be an option in nonemergency cases of gastrointestinal
involvement, while its efficacy in patients with parenchymal
involvement of the central nervous system is needs to be
further evaluated [40–42]. Adalimumab, a humanized IgG
1
monoclonal anti-TNF-𝛼 antibody, has been effective in reliev-
ing ocular involvement of BD, in particular when patients lost
efficacy to infliximab [36].
In the management of gastrointestinal involvement,
prior to surgery, sulfasalazine, corticosteroids, azathioprine,
thalidomide, and anti-TNF𝛼 agents should be employed [13].
With regard to ocular involvement, anterior uveitis can be
responsive to topical low-dose steroids, while patients with
retinal vasculitis, macular involvement, or severe uveitis,
defined as a >2-line drop in visual acuity on a 10/10 scale,
require azathioprine along with corticosteroids administered
orally (prednisone at a daily dosage of 1mg/kg) or intra-
venously (methylprednisolone at a daily dosage of 1 g for 3
days), combinedwith cyclosporine A or infliximab. Corticos-
teroids, azathioprine, cyclosporine A, and cyclophosphamide
are recommended in the management of acute deep vein
thrombosis [28, 29]. With regard to the management of
central nervous system involvement, corticosteroid therapy is
recommended for dural sinus thrombosis, while a combina-
tion therapy of corticosteroids with azathioprine, cyclophos-
phamide, methotrexate, anti-TNF-𝛼 agents, and interferon
may all be considered in cases of meningoencephalitis [13].
3. Rationale and Methods
There is currently no gold standard therapy for BD, and
increasing evidence of molecular and cellular pathways
involved in its pathogenesis continues to emerge. Recent data
have spread the promising therapeutic targets other than
TNF in patients with severe and refractory BD (Figure 1).
Therefore, we reviewed the available medical literature
to find all cases of BD treated with biological agents
other than TNF-inhibitors, using the PubMed database.
We matched the following search terms: “Behcet’s” and
“anakinra,” “canakinumab,” “gevokizumab,” “tocilizumab,”
“ustekinumab,” and “rituximab,” in order to find studies,
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including case reports and case series, showing all current
experiences and the most recent evidence regarding these
novel therapeutic approaches in BD.
4. Results
We found 44 cases of BD patients in therapy with biological
agents other than anti-TNF-𝛼 agents. In particular, we found
eight studies, describing 24 patients on IL-1 inhibitors [12, 43–
50], 13 treated with the IL-1𝛽 receptor antagonist anakinra
[12, 43, 44, 47, 48], 4 with the IL-1 blocker canakinumab [46,
49, 50], and 7, described in one open-label pilot study, with
the anti-IL-1 agent gevokizumab [45] (Table 1). Additionally,
7 patients were described being treated with the IL-6 receptor
antagonist tocilizumab [51–56], just 1 case with the anti-IL-
12/23R agent ustekinumab [57] (Table 2), and 12with the anti-
CD-20 agent rituximab [58–60] (Table 3).
4.1. Interleukin-1 Inhibition and Behcet’s Disease. The IL-1
superfamily comprises a group of 11 cytokines which regulate
many intracellular signaling pathways: IL-1𝛼 and IL-1𝛽 are
the most studied members, binding their receptor type I (IL-
1RI) and coreceptor-accessory protein (IL-1RAcP). While IL-
1𝛼 is expressed as a precursor and is constitutively present
in most cells of healthy subjects, IL-1𝛽, induced by several
cytokines as TNF-𝛼, IL-18, IL-1𝛼, and IL-1𝛽 itself, is mainly
produced bymonocytes, tissue macrophages, fibroblasts, and
dendritic cells [61]. IL-1𝛽 is the principal proinflammatory
cytokine, leading to the expression of many chemokines
and secondary mediators of inflammation and upregulating
innate immunity in response to infectious agents [61]. The
inactive precursor of IL-1𝛽 requires cleavage by an intra-
cellular cysteine protease, called caspase-1, which must be
activated to convert IL-1𝛽 into its bioactive form [61]. The
proinflammatory effects of IL-1 are due to the binding with
IL-1RI and IL-1RAcP, which together form a heterotrimeric
signalling-competent complex; additionally, IL-1𝛽 autoin-
duction represents an aspect of the autoinflammation that
characterizes many autoinflammatory disorders [62, 63]. IL-
1𝛽 involvement in BD is mainly linked to the evidence of
elevated amounts of IL-1𝛽 in the sera of patients with BD
and to the fact that IL-1𝛽 inhibition has induced a stable
clinical remission in different reports [61, 63–65]. Among the
available IL-1 blockers, the IL-1 receptor antagonist anakinra,
as well as canakinumab and gevokizumab, targeting the IL-
1 molecule directly, has been used in patients with BD and
provided encouraging preliminary data on the successful
IL-1 inhibition, leading to an increased interest in anti-IL-1
agents for managing BD [61, 63]. Anakinra is a recombinant
human IL-1 receptor antagonist that competes with IL-1𝛼
and IL-1𝛽 and thus inhibits the proinflammatory effects of
both cytokines: it has been approved for use in rheumatoid
arthritis (at a recommended dose of 100mg/day subcuta-
neously) and has been used off-label for a broad spectrum of
inflammatory conditions, bringing about a sustained disease
remission [61, 63]. In 2008 Botsios et al. reported one
BD patient presenting with fever, mucocutaneous involve-
ment, colon ischemic perforation, thrombosis, serositis, and
elevated inflammatory markers for whom infliximab was
withdrawn due to onset of mucosal abdominal abscesses:
anakinra (at the dosage of 100mg/day) was then started
in association with prednisolone (5mg/day), leading to
complete remission in only one week [43]. Two years later
Bilginer et al. reported a complete positive response to
anakinra (1mg/kg/day) in a febrile patient diagnosed with
familial Mediterranean fever and BD showing mucocuta-
neous involvement, arthritis, and secondary amyloidosis
[44]. Recently, Emmi et al. reported the efficacy of anakinra
(100mg/day) in a patient with mucosal, skin, joint, ocular,
and gastrointestinal involvement, in whom a combination
of anti-TNF agents and rituximab resulted inefficacious. In
this case, a complete positive response was reported at the
12-month followup visit [47]. Additionally, we have recently
reported the efficacy of anakinra (100mg/day) in a patient
with BD associated with sacroiliitis, in whom infliximab lost
its efficacy despite a concomitant high dosage of prednisone
(50mg/day). Complete remission was verified within a few
days, and prednisone was tapered to 5mg/day without any
relapses [48]. Recently, our group has also reported on
nine BD patients on anakinra: seven out of nine patients
responded to 100mg/day of anakinra, but two showed no
improvement. In six of the seven patients, responses to
anakinra were rapid (obtained within 1-2 weeks). Addi-
tionally, three out of four patients suffering from recurrent
uveitis showed a complete resolution of ocular inflammation.
Orogenital aphthosis and skin lesions were the most frequent
manifestations refractory to anakinra, with a poor response
in seven out of nine patients. In order to control mucocuta-
neous manifestations, colchicine was successfully introduced
in three patients. Thrombotic lesions during treatment with
anakinra occurred in two patients, and two others developed
retinal vasculitis after 8 months while were on anakinra [12].
In the end, one of two refractory patients achieved complete
resolution by increasing the anakinra dose to 150mg/day.
Canakinumab is a human monoclonal IgG
1
that selec-
tively neutralizes IL-1𝛽, inhibiting its binding to IL-1RI and all
cytokine-dependent signaling pathways: the half-life is 21–28
days, and recommended dose is 2mg/kg subcutaneously
in children or 150mg subcutaneously in adults every 8
weeks. Its safe and successful use has been demonstrated
in cryopyrin-associated periodic syndromes and systemic-
onset juvenile idiopathic arthritis [61, 63]. Canakinumab
administered as monotherapy has also recently been shown
to be efficacious in refractory BD, confirming that inhibition
of the proinflammatory effects of IL-1𝛽 is paramount in
controlling the clinical spectrum of BD [50]. Additionally,
our recent study has suggested that canakinumab given
every 6 weeks may be a suitable monodrug therapeutic
option for BD patients, confirming the prompt resolution
of all disease-related clinical manifestations without any
adverse event [50]. Just one patient, previously reported in
2012 when on canakinumab at a dosage of 150mg every 8
weeks [49], relapsed while was on this dosage, requiring a
shorter interval between canakinumab administrations [50]:
when canakinumab was administered at the same dosage
every 6 weeks a successful response was again obtained,
with a stable recovery of patient’s clinical picture [50]. One
of these patients was also unresponsive to anakinra but
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took advantage from canakinumab with complete resolution
of intraocular inflammation, fever, abdominal pain, and
headache within 2 weeks from the start of canakinumab
[50]. An additional case related to treatment of BS with
canakinumab has recently been published by Ugurlu et al.
In this report a single dose of 150mg of canakinumab was
effective in inducing a sustained resolution of BD clinical
manifestations, even the ocular ones, and in normalizing
all inflammation markers within a few weeks, after that
infliximab, adalimumab, and anakinra were all ineffective
[46].
Gevokizumab is a recombinant humanized anti-IL-1𝛽
antibody, that modulates IL-1𝛽 bioactivity by reducing the
affinity for its IL-1RI:IL-1RAcP signaling complex [61]: it has
recently been evaluated in BDpatients with refractory uveitis.
Further convincing evidence of IL-1𝛽 role in BD derives from
a trial based on gevokizumab in patients with multiresistant
and sight-threatening uveitis: following a single intravenous
infusion of gevokizumab (at the dosage of 0.3mg/kg) there
was a rapid complete resolution of intraocular inflammation
along with marked improvement in visual acuity within
21 days. In addition, five patients who were retreated with
gevokizumab for recurrent uveitis responded to a second
dose and maintained their response for several months,
despite discontinuation of immunosuppressive agents and
without the need to increase steroid dosage [45].
4.2. Interleukin-6 Inhibition and Behc¸et’s Disease. IL-6 is a
pleiotropic cytokine secreted by various cell types, including
T and B lymphocytes, macrophages, osteoblasts, fibrob-
lasts, keratinocytes, and endothelial cells, involved in many
immune pathways and playing a pivotal role in the regulation
of various immune responses, in the amplification of acute
inflammation, and in its progression into relapsing or chronic
inflammatory reactions [66]. Increased plasma IL-6 levels
have been reported in patients with BD, mainly in those
showing evidence of neurologic involvement, suggesting
a correlation with disease activity [67]. Tocilizumab is a
humanized monoclonal antibody which specifically inhibits
IL-6 by competitively blocking the binding site to the IL-
6 receptor, definitely approved for patients with rheuma-
toid arthritis refractory to traditional disease-modifying
antirheumatic drugs. However, due to the IL-6 effects on
immune system and inflammatory processes, IL-6 antago-
nism is now considered a potential therapeutic strategy even
in various autoinflammatory and autoimmune disorders [68,
69]. Seven BD patients treated with tocilizumab have been
reported [51–56]: all presented orogenital manifestations and
six of them cutaneous involvement; ocular involvement was
reported in four patients [51, 52, 54, 55], and one of these
also suffered from optic neuritis [54]. The reported dosage
of tocilizumab was 8mg/kg every 4 weeks [51–53, 55, 56]
or, alternatively, 480mg every 4 weeks [54]. Tocilizumab
monotherapy was used in three cases and brought about
complete remission in two [51, 54], while in the third it lost
efficacy after the third infusion [56]. Efficacy of tocilizumab
was also reported in combination with corticosteroids and
other drugs in other two patients [52, 53]. In particular, it
is noteworthy that complete remission under tocilizumab
was reported in combination with high-dose corticosteroids
[52, 53]: in the first case prednisone was used in a dose range
of 30–60mg once daily [52], while in the second prednisone
was used at the dosage of 1mg/kg/day in combination with
azathioprine; however, in the second case tocilizumab was
discontinued after the fourth infusion due to the occurrence
of a scrotal abscess due to Escherichia coli [53]. Another BD
patient with secondary amyloidosis, treated with colchicine
and tocilizumab, showed also a complete remission and
decreased proteinuria [55]. However, in another patient the
combination of tocilizumab and azathioprine was ineffica-
cious in the treatment of mucocutaneous manifestations
[56]. Notably, among BD patients successfully treated with
tocilizumab, six had failed to respond to anti-TNF agents [51–
54, 56] and one of these became resistant to anakinra and
other traditional immunosuppressive drugs [54].
4.3. Interleukin-12/23 Inhibition and Behcet’s Disease. Two
studies have shown increased serum levels of IL-12 and IL-23
in BD patients and also descripted a relationship of serum IL-
23 levels with ocular inflammatory activity [70, 71]. There is
increasing evidence supporting a link between several single
nucleotide polymorphisms of non-HLA and HLA genes and
susceptibility to BD [10, 72, 73]. In functional terms, IL-
12 and IL-23 are linked to the production of IFN-𝛾, which
in turn represents a pivotal mediator of inflammation in
peripheral tissues (skin, intestinal mucosa, and lung) by
means of multiple proinflammatory cytokines, such as TNF-
𝛼 and IL-1𝛼 [10]. Moreover, IL-12 and IL-23 share a p40
subunit and promote, respectively, Th1 differentiation and
Th17 pathway, which are both involved in the pathogenesis
of BD. IL-12, secreted by activated peripheral lymphocytes,
interacts with the B1 and B2 subunits of the IL-12 receptor on
both human T and natural killer cells, while IL-23, secreted
by dendritic cells and activated macrophages, binds to IL-12
receptor B1 and IL-23 receptor: both IL-12 and IL-23 have
crucial functions in the adaptive and innate immunity [74].
With regard to ustekinumab, a human monoclonal anti-
body against the common p40 subunit of IL-12 and IL-23
[75], only one case has been reported by Baerveldt et al.
[57]: the patient had BD with mucosal, ocular, intestinal,
and articular involvement, as well as psoriasis vulgaris and
hidradenitis suppurativa, which were successfully controlled
by subcutaneous injections of ustekinumab (at the dosage of
45mg at weeks 0 and 4 and every 12 weeks thereafter) within
3 months without adjunctive immunosuppressive treatment
[57].
4.4. B Cell Inhibition and Behcet’s Disease. Although there
is more extensive evidence of T cell involvement in BD,
several studies have suggested a possible pathogenetic role
of B cells and a potential close interaction between T
and B cells [76–79]. Rituximab is a chimeric monoclonal
antibody against CD20, a specific B cell differentiation
membrane antigen, participating in B cell activation and
proliferation [80], administered intravenously and approved
for use in lymphomas (375mg/m2/week for four cycles) [80]
and rheumatoid arthritis (1 g × 2/infusions, 2 weeks apart,
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with repeated courses decided on the individual clinical
evaluation) [81]. Rituximab off-label use has been increasing
in recent years for other immune-mediated diseases [82–84],
as well as for BD [58–60].
In a single-blind randomized controlled trial related to 20
patients with refractory BD involving the eye, 10 patients were
treated with rituximab (1 g × 2/infusions, 2 weeks apart) and
methotrexate (15mg/week) and 10 with cyclophosphamide
(monthly intravenous infusions of 1000mg), azathioprine
(2-3mg/kg/day), and prednisone (0.5mg/kg/day): rituximab
and methotrexate were found to be more effective than
traditional drugs in improving all the most dreadful ocular
manifestations [59]. Moreover, another BD patient with reti-
nal vasculitis refractory to azathioprine and corticosteroids
and intolerant to etanercept was successfully treated with
rituximab (1 g × 2/infusions, 2 weeks apart) [58]. A young
female patient with BD, in whom severe orogenital aphto-
sis, arthritis, and erythema nodosum were recurrent, who
was previously refractory to infliximab and etanercept, was
started on rituximab (at the dosage of 1 g given intravenously
every two weeks) combined with prednisone (15mg/day),
methotrexate (20mg/week) and colchicine: this treatment
was successful after the third rituximab infusion, allowing a
progressive reduction in the corticosteroid dosage [60].
5. Conclusive Remarks
The final goal in the treatment strategies of BD is to prevent
irreversible multisystemic damage: an ideal therapy should
be tailored according to the extent and severity of BD
heterogeneous clinical manifestations [11, 13]. Because of the
possibility of failure of traditional immunosuppressive and
anti-TNF agents, there is need for alternative therapeutic
tools with other modes of action, particularly for refractory
cases of BD. Based on recurrent inflammatory attacks, lack
of autoantibodies, and response to IL-1 inhibition in some
patients [12], BD could be depicted as a peculiar autoin-
flammatory disorder; on the other hand, BD shares with the
autoimmune diseases the possibility of being treated with
immunosuppressive agents, and therapeutic benefit observed
in patients treated with interferon supports the hypothesis
of a Th1-driven disease [85]. Although BD classification
as an autoinflammatory or autoimmune disorder is still a
matter of debate [1, 86, 87], the response to specific novel
therapies could provide clinical insights into the causal basis
of the syndrome. Multiple cytokines likely contribute to BD
pathological landscape, and it is doubtful that blocking a
single cytokine or a specific cell line will resolve all of the pro-
tean disease manifestations [34]. Among the newer therapies
studied to date, inhibition of IL-1𝛽, IL-6, and CD20 seems
to show the best results. Convincing evidence of IL1𝛽 role
in BD derives from a trial of gevokizumab in patients with
multiresistant uveitis [45] and from the successful experience
with anakinra [12, 43, 44, 47, 48] and canakinumab [46, 49,
50], while the increasing number of published reports of BD
patients treated with tocilizumab [51–56] and rituximab [58–
60] demonstrates the complex heterogeneous biochemical
scenery behind this syndrome. However, the number of
patients on these therapies is still low, making it difficult to
draw firm and definite conclusions. Therefore, further large
controlled studies involving BD patients and longer-term
follow-up periods are needed to corroborate these recent
observations and confirm the efficacy and safety of these
treatments, which provide a valuable addition to the current
therapeutic armamentarium in refractory BD.
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